Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80
Collaboration › Details

Merck (US)–Cowen: investor conference, 202103 supply service Merck presents at Cowen & Co Annual Health Care Conference 2021

 

Period Period 2021-03-03
Organisations Partner, 1st Merck & Co. Inc. (NYSE: MRK)
  Group Merck (US) (MSD) (Group)
  Partner, 2nd Cowen & Company LLC
  Group Cowen (Group)
Products Product Cowen & Co. Annual Health Care Conference 2021 DIGITAL
  Product 2 pharmaceutical
Person Person Clyburn, Frank (Merck (US) 202102 EVP + Chief Commercial Officer)
     

Merck & Co., Inc.. (2/24/21). "Press Release: Merck to Present at the Cowen 41st Annual Health Care Conference". Kenilworth, NJ.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Frank Clyburn, executive vice president and chief commercial officer, is scheduled to participate in the Cowen 41st Annual Health Care Conference on March 3, 2021 at 1:20 p.m. EST.

Investors, analysts, members of the media and the general public are invited to watch a live video webcast of the presentations at ¨
https://investors.merck.com/events-and-presentations/default.aspx.


About Merck

For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.


Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).


Media:
Patrick Ryan
(973) 275-7075

Investors:
Peter Dannenbaum
(908) 740-1037
Michael DeCarbo
(908) 740-1807

   
Record changed: 2021-02-26

Advertisement

Picture [iito] Fighting Customers 650x80px

More documents for Merck (US) (MSD) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top